Location
Areas of Expertise
About Me
Dr. Gombos is a Professor and Chief of the Section of Ophthalmology at the University of Texas MD Anderson Cancer Center, where he specializes in ocular oncology. He also serves as Clinical Co-Director of the Retinoblastoma Center of Houston and holds joint appointments at Baylor College of Medicine and the University of Texas Medical Branch.
His clinical expertise focuses on the diagnosis and management of eye cancers, including retinoblastoma, uveal melanoma, and other intraocular and conjunctival malignancies. Dr. Gombos provides comprehensive care for patients with these conditions, utilizing advanced surgical and medical treatments. He has been active in clinical research and has contributed to numerous studies in ocular oncology, including the development of prognostic tests and treatment protocols.
Dr. Gombos completed his medical education at Stanford University and advanced fellowship training in ocular oncology at leading institutions. He is board-certified in ophthalmology and is dedicated to improving outcomes for patients with ocular tumors through a multidisciplinary approach.
Training
Clinical in Ocular Oncology
2000Moorfields Eye Hospital & St. Bartholomew's Hospital, London
Fellowship
Heed in Ocular Oncology
1999University of California, San Francisco
Fellowship
Ophthalmology
1998Scheie Eye Institute
ResidencyTransitional Internship
1995Mercy Hospital & Medical Center
Residency
Doctor of Medicine
1994Stanford University
Medical School
Awards & Honors
America's Most Honored Doctors - The Best of the Best
2022American Registry
America's Best Ophthalmologists 2022
2022Newsweek
American Academy of Ophthalmology's Senior Achievement Award
2014American Academy of Ophthalmology
Publications & Press
Early genetic evolution of driver mutations in uveal melanoma
Nature communications•2025Multicentre analysis of nucleic acid quantification using aqueous humour liquid biopsy in uveal melanoma: implications for clinical testing
Can J Ophthalmol•202515-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)
J Clin Oncol•2024Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease
Oph•2024
Certifications & Licensure
- Licensed In
- TX
- License Numbers
- L3662


